SAB Biotherapeutics (NASDAQ:SABS) Given Buy Rating at Rodman & Renshaw

SAB Biotherapeutics (NASDAQ:SABS)‘s stock had its “buy” rating reissued by Rodman & Renshaw in a research report issued to clients and investors on Monday,Benzinga reports. They currently have a $13.00 price target on the stock. Rodman & Renshaw’s target price would suggest a potential upside of 216.30% from the company’s current price.

SABS has been the topic of several other reports. Zacks Research lowered SAB Biotherapeutics from a “hold” rating to a “strong sell” rating in a report on Thursday, March 12th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of SAB Biotherapeutics in a report on Friday, April 10th. HC Wainwright dropped their target price on SAB Biotherapeutics from $9.00 to $7.00 and set a “buy” rating on the stock in a report on Tuesday, March 10th. Chardan Capital raised their target price on SAB Biotherapeutics from $12.00 to $14.00 and gave the stock a “buy” rating in a report on Wednesday, March 11th. Finally, Wall Street Zen lowered SAB Biotherapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 14th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, SAB Biotherapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $10.50.

SAB Biotherapeutics Price Performance

Shares of SABS stock opened at $4.11 on Monday. The stock’s 50-day simple moving average is $3.88 and its 200-day simple moving average is $3.79. The company has a debt-to-equity ratio of 0.02, a quick ratio of 9.46 and a current ratio of 9.46. The firm has a market capitalization of $209.40 million, a PE ratio of -1.77 and a beta of 0.55. SAB Biotherapeutics has a fifty-two week low of $1.60 and a fifty-two week high of $6.60.

SAB Biotherapeutics (NASDAQ:SABS) last announced its quarterly earnings data on Monday, March 9th. The company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.30). Equities analysts expect that SAB Biotherapeutics will post -1.1 earnings per share for the current year.

Institutional Trading of SAB Biotherapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Commodore Capital LP acquired a new stake in SAB Biotherapeutics during the third quarter worth about $8,847,000. HB Wealth Management LLC acquired a new stake in SAB Biotherapeutics in the third quarter valued at approximately $618,000. Virtu Financial LLC purchased a new stake in shares of SAB Biotherapeutics in the third quarter valued at approximately $40,000. State of Wyoming acquired a new position in shares of SAB Biotherapeutics during the 4th quarter worth approximately $34,000. Finally, Dimensional Fund Advisors LP acquired a new position in shares of SAB Biotherapeutics during the 3rd quarter worth approximately $32,000. 7.82% of the stock is owned by institutional investors and hedge funds.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.